Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02746198
Other study ID # 14DE-KIEL-HPAAD1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 22, 2016
Est. completion date April 26, 2017

Study information

Verified date February 2021
Source Clinical Research Center Kiel GmbH
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to estimate the effect of a probiotic dairy drink on occurrence and duration of AAD and gastrointestinal symptoms during Helicobacter pylori (Hp) eradication therapy and during 4 weeks thereafter and calculating the sample size for a confirmatory study.


Description:

Helicobacter p. positive subjects aged ≥18 years with an indication for Helicobacter pylori (Hp) eradication recommended by a gastroenterologist should be included in the study. Subjects should be willing to consume 2 servings of the study product per day for 6 weeks, and to undergo an Hp eradication therapy for 14 days starting with the consumption period.


Recruitment information / eligibility

Status Completed
Enrollment 125
Est. completion date April 26, 2017
Est. primary completion date December 23, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Individuals, both genders, aged = 18 y - Helicobacter p. infected individuals, to which eradication therapy has been recommended by gastroenterologists - Willingness to undergo the Helicobacter p. eradication therapy - Willingness to abstain from food and supplements containing probiotics, prebiotics and fermented products except the study product - Written informed consent Exclusion Criteria: - Subjects currently enrolled in another interventional trial - subjects having finished another interventional trial within the last 4 weeks before inclusion - incapacity to comply with the study protocol - allergy or hypersensitivity to any component of the test product (allergy against milk protein) - allergy or hypersensitivity to any component of the eradication therapy (e.g. penicillin allergy) - acute GIT infections - chronic inflammatory bowel diseases (IBD) - irritable bowel syndrome (IBS) - any episode of diarrhea according to WHO criteria during the last 4 weeks before inclusion - history of lactose intolerance - severe chronic disease (cancer, malabsorption, malnutrition, severe chronic inflammatory diseases (except chronic gastritis), renal, hepatic or cardiac diseases, artificial cardiac valve, COPD, respiratory insufficiency) - history of active or persistent hepatitis B and C - known congenital, acquired or iatrogenic immunodeficiency (e.g. HIV, chemotherapy, immunosuppression) - systemic treatment with antibiotics during the last 4 weeks before inclusion - systemic treatment likely influencing absorption, metabolism and excretion of food ingredients (metoclopramide, laxatives, body weight management and/or medication etc.) - systemic treatment likely interfering or influencing effectiveness of the eradication drugs used e.g. ergotamine, statins, clopidogrel - regular medical treatment including OTC, which may have impact on the study aims (e.g. probiotics, antibiotic drugs, laxatives etc.) - severe neurological, cognitive or psychiatric diseases - surgery or intervention requiring general anaesthesia within 2 months before the study - vegan - eating disorders (e.g. anorexia, bulimia) - present alcohol and drug abuse - pregnancy or lactation - legal incapacity - blood parameters: - Hb < 12 g/dL - liver transaminases (ALT, AST) > 2-fold increased - serum creatinine out of the normal range - subjects who are scheduled to undergo hospitalization during the study period

Study Design


Related Conditions & MeSH terms


Intervention

Other:
probiotic dairy drink

acidified milk


Locations

Country Name City State
Germany CRC Clinical Research Center Kiel Kiel Schleswig-Holstein

Sponsors (2)

Lead Sponsor Collaborator
Clinical Research Center Kiel GmbH Yakult Honsha Co., LTD

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Occurrence of antibiotic-associated diarrhea (AAD) Occurrence of antibiotic-associated diarrhea (AAD) (as defined by number of subjects with diarrhea within the intervention period of 6 weeks after starting antibiotic treatment; diarrhea is defined according WHO 6 weeks
Secondary Cumulated duration of antibiotic-associated diarrhea (AAD) Number of days with diarrhea within the intervention period 6 weeks
Secondary Gastrointestinal Symptom Rating Scale Standardized questionnaire according Dimenäs et al. 6 weeks
Secondary Cumulative sverity of antibiotic-associated diarrhea (AAD) Sum of the values (obtained by transformation of Bristol stool form types) of all stools during days with diarrhea (transformation of Bristol scale types is defined: type 1 to 4 = 0; type 5 = 1; type 6 = 2 and type 7 = 3) 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT03181516 - Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics Phase 2
Recruiting NCT03895593 - Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
Completed NCT00382304 - A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea Phase 2
Completed NCT04212403 - Antibiotic Prophylaxis in Transurethral Prostate Resection (TURP) and Transurethral Bladder Tumour Resection (TURB) N/A
Terminated NCT02900196 - Effect of a Fresh Fermented Dairy Drink Product Consumption on Antibiotic Associated Diarrhea and Gastro-Intestinal Disorders N/A
Completed NCT01782755 - Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial Phase 2
Completed NCT06109740 - Probiotics For The Prevention of Antibiotics Associated Diarrhea in the Pediatric Intensive Care Unit N/A
Suspended NCT00591357 - Efficacy of Loperamide for C. Difficile Colitis and Other Diarrheal Diseases Associated With Antibiotic Therapy Phase 4
Completed NCT00700557 - Probiotics at the Treatment of Antibiotic Associated Diarrhea Phase 4
Active, not recruiting NCT03256708 - Prevention of Antibiotic-Associated Diarrhoea With Prolardii N/A
Completed NCT04321460 - Study of LRG-002 Hard Capsules (Lek d.d., Slovenia) Used in the Prophylaxis of Antibiotic-associated Diarrhea in Adults. Phase 3
Completed NCT05607056 - Efficacy and Safety of Sinquanon for Prevention of Antibiotic-associated Diarrhea in Adults N/A
Recruiting NCT05845073 - The Efficacy of a Probiotic for Antibiotic Associated Gastrointestinal Symptoms N/A
Completed NCT02127814 - Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile N/A
Completed NCT01143623 - Dose Response Effect of Probiotics for the Prevention of Antibiotic-associated Diarrhea in Chinese Adults Phase 2/Phase 3
Completed NCT00641199 - Probiotics for Prevention of Antibiotic-associated Diarrhea N/A
Completed NCT02462590 - Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial Phase 4
Terminated NCT01143272 - Probiotic Saccharomyces Boulardii for the Prevention of Antibiotic-associated Diarrhoea Phase 3
Completed NCT03755765 - Mechanisms of Preventing Antibiotic-Associated Diarrhea and the Role for Probiotics Early Phase 1
Completed NCT05990972 - Clinical Study of Fecal Microbiota Transplantation in the Treatment of Antibiotic-associated Diarrhea N/A